The Access to PrEP Act adds a new Section 10A to Nova Scotia’s Fair Drug Pricing Act to treat antiviral drugs prescribed for pre‑exposure prophylaxis (PrEP) against HIV as a covered benefit under the province’s drug program and to prohibit any copayment for those drugs. The amendment overrides subsection 10(1) of the Act so PrEP drugs are expressly “deemed to be a benefit,” and it states that no copayment may be charged in connection with those drugs.
This is a narrow, focused change: it mandates coverage and eliminates patient copays for PrEP but does not name specific products, set clinical eligibility rules, or allocate new funds. That simplicity speeds implementation but leaves key operational questions — which formulations count, how pharmacies handle dispensing and professional fees, and how the program will track and budget for higher uptake — to administrative policy and regulation.
At a Glance
What It Does
The bill inserts Section 10A into the Fair Drug Pricing Act, deeming antiviral drugs used for HIV pre‑exposure prophylaxis to be a benefit under the Act and prohibiting copayments for those drugs. It explicitly overrides subsection 10(1) to ensure PrEP coverage regardless of the existing benefit‑designation process.
Who It Affects
People eligible for PrEP under clinical guidelines in Nova Scotia, clinicians and sexual health clinics that prescribe PrEP, the provincial drug program (Pharmacare), and pharmacies that dispense these antiviral drugs. It also affects public‑health budgeting and organizations involved in HIV prevention.
Why It Matters
Removing copayments lowers a well‑documented access barrier to PrEP and could increase uptake and reduce new HIV infections, which has downstream health system savings. The bill establishes a legal coverage baseline but leaves many program‑design details to the department — creating both opportunity for rapid access and uncertainty about implementation and costs.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act is short and targeted. It amends the Fair Drug Pricing Act by adding a two‑paragraph section: one paragraph says antiviral drugs for the purpose of pre‑exposure prophylaxis against HIV are to be treated as a covered benefit, and the second paragraph says no copayment may be charged for those drugs.
Because the new provision is “notwithstanding subsection 10(1),” it overrides whatever process or criteria subsection 10(1) establishes for declaring benefits.
Practically, the government will need to translate that statutory directive into operational rules: decide which specific drug products and formulations fall under the phrase “antiviral drugs for the purpose of pre‑exposure prophylaxis,” determine whether clinical criteria or prior authorizations apply, and update the provincial formulary and claims systems so pharmacies can bill the program with no copayment collected from patients. The bill does not list drugs (for example, oral tenofovir/emtricitabine or long‑acting cabotegravir) nor does it mention non‑drug charges such as dispensing fees or pharmacist professional services.Because the Act does not create new spending language or an explicit appropriation, the coverage mandate will operate within existing drug program structures and budgets.
That means the department administering the Fair Drug Pricing Act must absorb extra pharmacy claims or identify offsets. The legislation is silent on timing, reporting requirements, or enforcement mechanisms for the copayment prohibition, so practical implementation will depend on regulatory updates, administrative guidance to pharmacies, and internal budgeting decisions.
The Five Things You Need to Know
The bill adds Section 10A to the Fair Drug Pricing Act; Section 10A(1) deems antiviral drugs used for HIV pre‑exposure prophylaxis to be a benefit, overriding subsection 10(1).
Section 10A(2) prohibits any copayment in connection with antiviral drugs used for PrEP — patients cannot be charged a copay for those medications under the Act.
The text does not name specific drugs or formulations, leaving open whether oral PrEP (e.g.
tenofovir/emtricitabine) and long‑acting injectable PrEP (e.g.
cabotegravir) are both covered without further administrative action.
The Act does not address dispensing fees, pharmacist professional fees, or related service charges, so pharmacies may still seek compensation through those channels unless the program’s payment rules are changed.
The bill contains no implementation timeline, budget appropriation, or enforcement provisions, meaning coverage and copayment elimination require administrative steps before patients experience concrete changes.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title — Access to PrEP Act
This single line establishes the Act’s short title. It has no operational effect but signals legislative intent and will be the citation used in regulations and administrative guidance.
Deem PrEP antiviral drugs to be a covered benefit
Section 10A(1) says that “antiviral drugs for the purpose of pre‑exposure prophylaxis from human immunodeficiency viruses are deemed to be a benefit.” By using “notwithstanding subsection 10(1),” the clause removes any barrier in subsection 10(1) that might otherwise delay or limit benefit designation. Administratively, this forces the drug program to treat eligible PrEP products as part of the benefit package even if they were not previously on the formulary or subject to existing benefit rules.
Prohibition on copayments for PrEP drugs
Section 10A(2) states that no copayment may be charged in connection with antiviral drugs used for PrEP. The provision is categorical — it does not create exemptions or thresholds — but it does not define the phrase “copayment” beyond the ordinary meaning. That means program rules, pharmacy billing systems, and contracts will have to be updated to prevent collection of patient copays for covered PrEP medications; however, the provision does not expressly alter or prohibit other fees or charges not typically characterized as copayments.
This bill is one of many.
Codify tracks hundreds of bills on this topic across all five countries.
Explore this topic in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People eligible for PrEP in Nova Scotia — removes the direct financial barrier of copayments and can increase access for individuals at elevated risk of HIV.
- Public health programs and sexual health clinics — easier linkage to no‑cost medication should improve prevention outcomes and simplify counselling and navigation for clients.
- Community organizations serving populations at higher risk (e.g., MSM, trans people, people who inject drugs) — can refer clients to a drug program that legally covers PrEP and eliminate cost as an access excuse.
- Clinicians who prescribe PrEP — lower administrative friction for patients may increase adherence and retention in preventive care, simplifying follow‑up and monitoring.
Who Bears the Cost
- Nova Scotia’s public drug program (Pharmacare) and ultimately provincial taxpayers — the program will absorb medication costs previously paid by patients or private insurers unless offset elsewhere in the budget.
- Program administrators and the Department of Health — responsible for updating formularies, claims systems, and guidance without the bill creating a separate appropriation or implementation funding.
- Pharmacies and pharmacists — unless the program adjusts dispensing fee schedules or professional service payments, pharmacies may face administrative changes to billing and potential disputes about non‑copay charges.
- Private insurers and third‑party payors — may see changes in cost distribution and could adjust their coverage or premiums in response to increased public coverage of PrEP.
Key Issues
The Core Tension
The central dilemma is balancing access and cost control: the bill removes a direct financial barrier to an effective prevention tool, improving equity and public health outcomes, but it shifts costs onto a constrained public drug budget without prescribing offsets or implementation resources — forcing the government to choose between absorbing costs, restricting eligibility administratively, or reallocating funds from other priorities.
The bill’s brevity is both its strength and its primary challenge. It creates a firm legal requirement to cover PrEP and to ban copayments, but it leaves the practical boundaries undefined.
Key operational questions — which drug products qualify, whether injectable PrEP counts, how to handle combination products, and whether clinical eligibility criteria or prior authorization remain — are deferred to administrative practice. That creates short‑term uncertainty for prescribers, pharmacies, and patients.
Budgetary and payment mechanics are unresolved. The Act does not appropriate funds or amend payment rules for dispensing and professional fees.
If the public program simply covers medication costs but not related pharmacy fees, pharmacies may push to recover those amounts through other channels, or the department may need to renegotiate fee schedules. Additionally, the law does not place reporting or monitoring obligations on the ministry, so measuring uptake and fiscal impact will require ad hoc data collection unless regulations or guidance add formal metrics.
There's more to this law than the bill.
Codify Laws traces every connection across the legislative lifecycle.